KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Silexion Therapeutics Corp has completed a significant preclinical study evaluating its RNA interference therapeutic candidate, SIL204, for various KRAS-driven cancers, including colorectal and ...

One of the first and most promising uses scientists envision for the rapidly evolving technology of quantum computing is a new approach to drug development.

The precision oncology landscape is experiencing a potential breakthrough with Silexion Therapeutics' innovative approach to addressing KRAS-driven cancers. KRAS mutations represent one of the ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

Tadaaki Taniguchi, M.D., Ph.D., Chief Research & Development Officer, Astellas | Astellas’ Chief R&D Officer, Tadaaki ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like ...

Clinicians and scientists from RWJBarnabas Health and Rutgers Cancer Institute will share new findings and lead discussions ...